<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: future financial condition", fill: "#3cd070"},
{source: "3: future financial condition", target: "3: operations", fill: "#3cd070"},
{source: "3: operations", target: "3: inherent risks", fill: "#3cd070"},
{source: "3: inherent risks", target: "3: uncertainties", fill: "#3cd070"},
{source: "3: uncertainties", target: "3: could differ materially from", fill: "#3cd070"},
{source: "3: could differ materially from", target: "3: effective drugs", fill: "#3cd070"},
{source: "3: effective drugs", target: "3: clinical trials", fill: "#3cd070"},
{source: "3: clinical trials", target: "3: economically", fill: "#3cd070"},
{source: "3: economically", target: "3: timely manufacture sufficient amounts", fill: "#3cd070"},
{source: "3: timely manufacture sufficient amounts", target: "3: manufacture", fill: "#3cd070"},
{source: "3: manufacture", target: "3: requisite quality", fill: "#3cd070"},
{source: "3: requisite quality", target: "3: commercialization activities", fill: "#3cd070"},
{source: "3: commercialization activities", target: "3: successfully finance", fill: "#3cd070"},
{source: "3: successfully finance", target: "3: commercialize", fill: "#3cd070"},
{source: "3: commercialize", target: "3: gaining market acceptance", fill: "#3cd070"},
{source: "3: gaining market acceptance", target: "3: manage relationships with collaboration partners", fill: "#3cd070"},
{source: "3: manage relationships with collaboration partners", target: "3: successfully enforce patent", fill: "#3cd070"},
{source: "3: successfully enforce patent", target: "3: proprietary rights protection", fill: "#3cd070"},
{source: "3: proprietary rights protection", target: "3: variability", fill: "#3cd070"},
{source: "3: variability", target: "3: royalty license", fill: "#3cd070"},
{source: "3: royalty license", target: "3: adjustments", fill: "#3cd070"},
{source: "3: adjustments", target: "3: amounts paid", fill: "#3cd070"},
{source: "3: amounts paid", target: "3: third parties", fill: "#3cd070"},
{source: "3: third parties", target: "3: former attorneys under", fill: "#3cd070"},
{source: "3: former attorneys under", target: "3: arbitration award", fill: "#3cd070"},
{source: "3: arbitration award", target: "3: manufacturing", fill: "#3cd070"},
{source: "3: manufacturing", target: "3: facilities costs", fill: "#3cd070"},
{source: "3: facilities costs", target: "3: effectively", fill: "#3cd070"},
{source: "3: effectively", target: "3: accordance with regulatory requirements", fill: "#3cd070"},
{source: "3: accordance with regulatory requirements", target: "3: establish comparability", fill: "#3cd070"},
{source: "3: establish comparability", target: "3: bulk drug substances", fill: "#3cd070"},
{source: "3: bulk drug substances", target: "3: enter into future collaboration agreements", fill: "#3cd070"},
{source: "3: enter into future collaboration agreements", target: "3: development activities", fill: "#3cd070"},
{source: "3: development activities", target: "3: drug withdrawal from", fill: "#3cd070"},
{source: "3: drug withdrawal from", target: "3: market due", fill: "#3cd070"},
{source: "3: market due", target: "3: serious adverse reactions", fill: "#3cd070"},
{source: "3: serious adverse reactions", target: "3: marketed drug", fill: "#3cd070"},
{source: "3: marketed drug", target: "3: secure licenses from third parties", fill: "#3cd070"},
{source: "3: secure licenses from third parties", target: "3: competition", fill: "#3cd070"},
{source: "3: competition", target: "3: technological", fill: "#3cd070"},
{source: "3: technological", target: "3: future regulations affecting", fill: "#3cd070"},
{source: "3: future regulations affecting", target: "3: affecting", fill: "#3cd070"},
{source: "3: affecting", target: "3: content timing", fill: "#3cd070"},
{source: "3: content timing", target: "3: submissions", fill: "#3cd070"},
{source: "3: submissions", target: "3: decisions", fill: "#3cd070"},
{source: "3: decisions", target: "3: regulatory agencies", fill: "#3cd070"},
{source: "3: regulatory agencies", target: "3: Contents ", fill: "#3cd070"},
{source: "3: Contents ", target: "3: governmental", fill: "#3cd070"},
{source: "3: governmental", target: "3: pharmaceutical industries", fill: "#3cd070"},
{source: "3: pharmaceutical industries", target: "3: affect coverage", fill: "#3cd070"},
{source: "3: affect coverage", target: "3: reimbursement", fill: "#3cd070"},
{source: "3: reimbursement", target: "3: scientists", fill: "#3cd070"},
{source: "3: future financial condition", target: "6: Successful ", fill: "#fefe22"},
{source: "6: Successful ", target: "6: development", fill: "#fefe22"},
{source: "6: development", target: "6: therapeutic monoclonal antibodies", fill: "#fefe22"},
{source: "6: Successful ", target: "73: cannot assure", fill: "#ffa343"},
{source: "73: cannot assure", target: "73: collaboration agreements", fill: "#ffa343"},
{source: "73: cannot assure", target: "START_HERE", fill: "#ffa343"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Demonstrate</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Condor">Operation Condor</a></td>
      <td>Operation Condor (Spanish: Operación Cóndor, also known as Plan Cóndor; Portuguese: Operação Condor) was a United States-backed campaign of political repression and state terror involving intelligence operations and assassination of opponents. It was officially and formally implemented in November 1975 by the right-wing dictatorships of the Southern Cone of South America.Due to its clandestine nature, the precise number of deaths directly attributable to Operation Condor is highly disputed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_Consent">Manufacturing Consent</a></td>
      <td>Manufacturing Consent: The Political Economy of the Mass Media is a 1988 book by Edward S. Herman and Noam Chomsky. It argues that the mass communication media of the U.S. "are effective and powerful ideological institutions that carry out a system-supportive propaganda function, by reliance on market forces, internalized assumptions, and self-censorship, and without overt coercion", by means of the propaganda model of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Textile_manufacturing">Textile manufacturing</a></td>
      <td>Textile manufacturing is a major industry. It is largely based on the conversion of fibre into yarn, then yarn into fabric.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_engineering">Manufacturing engineering</a></td>
      <td>Manufacturing engineering is a branch of professional engineering that shares many common concepts and ideas with other fields of engineering such as mechanical, chemical, electrical, and industrial engineering. \nManufacturing engineering requires the ability to plan the practices of manufacturing; to research and to develop tools, processes, machines and equipment; and to integrate the facilities and systems for producing quality products with the optimum expenditure of capital.The manufacturing or production engineer's primary focus is to turn raw material into an updated or new product in the most effective, efficient &amp; economic way possible.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_cost">Manufacturing cost</a></td>
      <td>Manufacturing cost is the sum of costs of all resources consumed in the process of making a product. The manufacturing cost is classified into three categories: direct materials cost, direct labor cost and manufacturing overhead.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Murata_Manufacturing">Murata Manufacturing</a></td>
      <td>Murata Manufacturing Co., Ltd. (株式会社村田製作所, Kabushiki-gaisha Murata Seisakusho) is a Japanese manufacturer of electronic components, based in Nagaokakyo, Kyoto.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_manufacturing">Pharmaceutical manufacturing</a></td>
      <td>Pharmaceutical manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs as part of the pharmaceutical industry.  The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2011_military_intervention_in_Libya">2011 military intervention in Libya</a></td>
      <td>On 19 March 2011, a multi-state NATO-led coalition began a military intervention in Libya, to implement United Nations Security Council Resolution 1973, in response to events during the First Libyan Civil War. With ten votes in favour and five abstentions, the UN Security Council's intent was to have "an immediate ceasefire in Libya, including an end to the current attacks against civilians, which it said might constitute "crimes against humanity" ...</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Alisher_Usmanov">Alisher Usmanov</a></td>
      <td>Alisher Burkhanovich Usmanov (Russian: Алишер Бурханович Усманов; born 9 September 1953) is an Uzbek-born Russian businessman and oligarch. By 2022, Usmanov had an estimated net worth of $19.5 billion and was among the world's 100 wealthiest people.Usmanov made his wealth after the collapse of the Soviet Union, through metal and mining operations, and investments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tourism_in_Abkhazia">Tourism in Abkhazia</a></td>
      <td>Tourism in Abkhazia is possible under Georgian law for foreigners entering the occupied territory from Georgia, although Georgia cannot assure the safety inside disputed territory.\nHowever, the Abkazian beaches on the Black Sea continue to be accessible for tourists coming from the Russian side of the Abkhazia–Russia border which is not under Georgian control.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medical_license">Medical license</a></td>
      <td>A medical license is an occupational license that permits a person to legally practice medicine. In most countries, a person must have a medical license bestowed either by a specified government-approved professional association or a government agency before he or she can practice medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Synchroscope">Synchroscope</a></td>
      <td>In AC electrical power systems, a synchroscope is a device that indicates the degree to which two systems (generators or power networks) are synchronized with each other.For two electrical systems to be synchronized, both systems must operate at the same frequency, and the phase angle between the systems must be zero (and two polyphase systems must have the same phase sequence). Synchroscopes measure and display the frequency difference and phase angle between two power systems.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/What's_Your_Raashee?">What's Your Raashee?</a></td>
      <td>What's Your Raashee? (lit. 'What's Your Zodiac Sign?') is a 2009 Indian Hindi-language romantic comedy film written and directed by Ashutosh Gowariker.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>TANOX INC      ITEM 1A Risk Factors        Some  of  the  information in this <font color="blue">Annual Report </font>on Form 10-K contains     forward-looking statements</td>
    </tr>
    <tr>
      <td>We typically identify forward-looking statements     by  using  terms  such  as “may,” “should,” “could,” “expect,” “plan,”     “anticipate,” “believe,” “estimate,” “predict,” “potential,” “objective,”     “intend”  or  similar  words, although we express some forward-looking     statements  <font color="blue">differently</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future <font color="blue">financial condition</font></font> and results of     <font color="blue">operations</font>,  as well as any forward-looking statements, are subject to     <font color="blue">inherent risks</font> and <font color="blue">uncertainties</font>, including but not limited to the risk     factors set forth below, and actual results <font color="blue">could differ <font color="blue">materially</font> from</font>     those projected or assumed in the forward-looking statements due to a number     of factors, including:           •   our ability to develop safe and <font color="blue"><font color="blue">effective</font> drugs</font>;           •   failure to achieve positive results in preclinical and toxicology     studies in animals or <font color="blue"><font color="blue">clinical trial</font>s</font> in humans;           •   failure to <font color="blue">economically</font> and <font color="blue">timely <font color="blue">manufacture</font> sufficient amounts</font> of     our products with the <font color="blue">requisite quality</font> for <font color="blue"><font color="blue">clinical trial</font>s</font> and     <font color="blue"><font color="blue">commercialization</font> activities</font>;           •   failure to receive, or delay in receiving, marketing approval for our     products;           •   failure to <font color="blue"><font color="blue">successfully</font> finance</font> and <font color="blue">commercialize</font> our products,     including <font color="blue">gaining <font color="blue">market <font color="blue">acceptance</font></font></font>;           •   our ability to <font color="blue">manage <font color="blue">relationship</font>s with <font color="blue"><font color="blue">collaboration</font> partners</font></font>;           •   our ability to obtain, maintain and <font color="blue"><font color="blue">successfully</font> enforce patent</font> and     other <font color="blue"><font color="blue"><font color="blue">proprietary</font> rights</font> protection</font> of our products;           •   <font color="blue">variability</font> of royalty, license and other revenues, and potential     <font color="blue">adjustments</font> and changes in <font color="blue">amounts paid</font> to us and amounts we may be required     to pay to <font color="blue">third parties</font>, including our <font color="blue">former attorneys under</font> an adverse     <font color="blue"><font color="blue">arbitration</font> award</font>;           •   our ability to use our <font color="blue">manufacturing</font> <font color="blue">capacity</font> and <font color="blue"><font color="blue">facilities</font> costs</font>     <font color="blue"><font color="blue">effective</font>ly</font> and in <font color="blue"><font color="blue">accordance</font> with <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font></font>;           •   our ability to <font color="blue">establish comparability</font> of our <font color="blue">bulk drug substances</font>     before and after <font color="blue">manufacturing</font> changes;           •   our ability to <font color="blue">enter into future <font color="blue">collaboration</font> <font color="blue">agreements</font></font> to support     our research and <font color="blue"><font color="blue">development</font> activities</font>;           •   <font color="blue">drug withdrawal from</font> the <font color="blue">market due</font> to <font color="blue">serious adverse reactions</font>     caused by the <font color="blue">marketed drug</font>;           •   our ability to secure licenses from <font color="blue">third parties</font> holding patents that     may affect the <font color="blue">manufacture</font> or marketing of our products;           •   <font color="blue">competition</font> and <font color="blue">technological</font> change;           •   existing and <font color="blue">future <font color="blue">regulations</font> <font color="blue">affecting</font></font> our business, including the     content, timing of <font color="blue">submissions</font> and <font color="blue">decisions</font> made by the FDA and other     <font color="blue"><font color="blue">regulatory</font> agencies</font>;                                           17     ______________________________________________________________________    [48]Table of <font color="blue">Contents       </font>  •   <font color="blue"><font color="blue">government</font>al</font> changes <font color="blue">affecting</font> Medicare and the healthcare and     <font color="blue"><font color="blue">pharmaceutical</font> industries</font> including policies that <font color="blue">affect coverage</font> and levels     of <font color="blue">reimbursement</font> for sales of our products; and           •   our ability to hire and retain experienced managers and <font color="blue">scientists</font></td>
    </tr>
    <tr>
      <td>The following section <font color="blue">discusses important risks</font> and <font color="blue">uncertainties</font> that could     <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> our business, results of <font color="blue">operations</font> and     <font color="blue">financial condition</font>, which in turn could <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> the     <font color="blue">trading price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font>Risks        Developing  <font color="blue">therapeutic</font>  <font color="blue">monoclonal <font color="blue">antibodies</font></font> is expensive and highly     uncertain</td>
    </tr>
    <tr>
      <td><font color="blue">Successful  </font><font color="blue">development</font> of <font color="blue">therapeutic</font> <font color="blue">monoclonal <font color="blue">antibodies</font></font> is highly     uncertain</td>
    </tr>
    <tr>
      <td>First, we <font color="blue">must discover</font> or otherwise acquire <font color="blue">drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Then we <font color="blue">must <font color="blue">demonstrate</font> through preclinical studies</font> and <font color="blue"><font color="blue">clinical trial</font>s</font>     that our products are safe and <font color="blue">effective</font> for use in a <font color="blue">particular target</font>     <font color="blue">indication</font> before we can obtain <font color="blue"><font color="blue">regulatory</font> approvals</font> to sell our products     <font color="blue">commercially</font> to that patient group</td>
    </tr>
    <tr>
      <td>These studies and <font color="blue">trials tend</font> to be very     costly and time consuming</td>
    </tr>
    <tr>
      <td>Furthermore, the results of preclinical studies     and initial <font color="blue"><font color="blue">clinical trial</font>s</font> of our products do not <font color="blue">necessarily</font> predict the     results from later-stage <font color="blue"><font color="blue">clinical trial</font>s</font>, which must <font color="blue">demonstrate</font> the desired     safety and efficacy traits</td>
    </tr>
    <tr>
      <td>Products that appear promising in research or early phases of <font color="blue">development</font>     may not <font color="blue">reach later stages</font> of <font color="blue">development</font> or be submitted for marketing     approval for a number of reasons, including:           •   <font color="blue">Preclinical </font><font color="blue">tests indicate</font> that the product is toxic or otherwise     <font color="blue">lacks efficacy</font> in animals;           •   The product is found to be less <font color="blue">effective</font> than required or causes     <font color="blue">serious adverse reactions</font> or side effects in <font color="blue">patients participating</font> in     <font color="blue"><font color="blue">clinical trial</font>s</font>; often these <font color="blue">reactions may</font> not be detectable in small, early     <font color="blue">stage trials</font> and can only be identified when the product is <font color="blue">administered</font> to     a larger patient base, as in Phase 3 trials or <font color="blue">following market approval</font>;           •   The <font color="blue">commercial introduction</font> of <font color="blue">competitive drugs</font> that may have greater     efficacy or <font color="blue">safety than</font> our product or <font color="blue">otherwise <font color="blue">adversely</font> impact</font> the     risk/benefit profile of our product;           •   We are unable to develop <font color="blue">manufacturing</font> methods that are <font color="blue">efficient</font>,     cost-<font color="blue">effective</font> and capable of <font color="blue">meeting stringent <font color="blue">regulatory</font> standards</font>; and           •   <font color="blue">Proprietary </font>rights of <font color="blue">third parties</font> may cover our products, and we are     not able to <font color="blue">secure licenses on <font color="blue">reasonable terms</font></font></td>
    </tr>
    <tr>
      <td>Our products other than Xolair require <font color="blue"><font color="blue">significant</font> <font color="blue">additional</font> <font color="blue">laboratory</font></font>     <font color="blue">development</font> or <font color="blue"><font color="blue">clinical trial</font>s</font> before they can be submitted for marketing     approval</td>
    </tr>
    <tr>
      <td>We have limited <font color="blue">capacity</font> to conduct and manage <font color="blue"><font color="blue">clinical trial</font>s</font>,     and we rely on <font color="blue">third parties</font>, <font color="blue">potentially</font> including <font color="blue">collaborative partners</font>     and <font color="blue">contract research organizations</font>, to <font color="blue">assist us</font> in these efforts</td>
    </tr>
    <tr>
      <td>Our     reliance on <font color="blue">third parties</font> may result in delays in completing, or failing to     complete,  <font color="blue"><font color="blue">clinical trial</font>s</font> if our <font color="blue">collaborators</font> or <font color="blue"><font color="blue">contractors</font> fail</font> to     perform under our <font color="blue"><font color="blue">agreements</font> with them</font></td>
    </tr>
    <tr>
      <td>If our large-scale trials are not     successful  or  we  are  otherwise  unable  to  satisfy the BLA filing     <font color="blue"><font color="blue">requirement</font>s</font>, we would not be able to recover our substantial <font color="blue">investment</font> in     developing the product</td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________    [49]Table of <font color="blue">Contents       </font>We may be unable to <font color="blue">enroll sufficient patients</font> in a <font color="blue">timely manner</font> in order     to complete our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">speed with which</font> we are able to <font color="blue">enroll patients</font> in <font color="blue"><font color="blue">clinical trial</font>s</font> is an     important factor in determining how quickly we may complete <font color="blue"><font color="blue">clinical trial</font>s</font>     and  the  cost  of  running  those trials</td>
    </tr>
    <tr>
      <td>Many <font color="blue">factors affect patient</font>     <font color="blue">enrollment</font>, including the size of the <font color="blue">patient population</font>, the proximity of     patients  to  clinical  sites, the <font color="blue">eligibility criteria</font> for the study,     perceived risks and benefits of the drug under study, whether the drug will     continue to be made available to the <font color="blue">patient following <font color="blue">completion</font></font> of the     trial,  the  success  of our personnel in making the <font color="blue"><font color="blue">arrangements</font> with</font>     <font color="blue">potential clinical sites</font> and other <font color="blue">ongoing trials <font color="blue">directed at</font></font> the same     <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>Any of these factors may make it <font color="blue">difficult</font> for us to enroll     enough patients to complete trials</td>
    </tr>
    <tr>
      <td>Delays in patient <font color="blue">enrollment</font> will result in increased costs and program     delays, which could slow down our product <font color="blue">development</font> and approval process</td>
    </tr>
    <tr>
      <td>Even if the trials are ultimately completed and the product is approved for     sale, a <font color="blue">program delay could compromise</font> the <font color="blue">commercial viability</font> of our drug     relative to competitive therapies, which could <font color="blue">materially</font> harm our business     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we do not receive and maintain <font color="blue"><font color="blue">regulatory</font> approvals</font>, we will not be able     to market our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">bio<font color="blue">technology</font></font> and <font color="blue"><font color="blue">pharmaceutical</font> industries</font> are subject to stringent     regulation  with  respect  to  product  safety and <font color="blue">efficacy by various</font>     <font color="blue">international</font>,  federal,  state  and  <font color="blue">local <font color="blue">authorities</font></font></td>
    </tr>
    <tr>
      <td>Of particular     significance   are  the  FDA’s  <font color="blue"><font color="blue">requirement</font>s</font>  covering  R&amp;D,  testing,     <font color="blue">manufacturing</font>, quality control, labeling and promotion of drugs for human     use</td>
    </tr>
    <tr>
      <td>A bio<font color="blue">therapeutic</font> cannot be marketed in the US until it has been     <font color="blue">approved by</font> the FDA, and then can only be marketed for the <font color="blue">indication</font>s     <font color="blue">approved by</font> the FDA As a result of these <font color="blue"><font color="blue">requirement</font>s</font>, the length of time,     the  level of <font color="blue">expenditures</font> and the <font color="blue">laboratory</font> and clinical information     required for approval of a Biologics License Application, are substantial     and can require a number of years</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">collaboration</font> partners</font> have <font color="blue">secured approval</font> to market Xolair in 41     countries,  including <font color="blue">the US and the European Union</font></td>
    </tr>
    <tr>
      <td>Tanox has not prepared or submitted any <font color="blue">marketing approval <font color="blue">applications</font></font> to     the FDA or any other <font color="blue"><font color="blue">regulatory</font> agency</font> for any of its products</td>
    </tr>
    <tr>
      <td>The FDA can     delay, limit or not <font color="blue">grant marketing approval</font> for our products for many     reasons, including:           •   their belief that a <font color="blue">product candidate</font> is not safe and <font color="blue">effective</font>;           •   their <font color="blue">interpretation</font> of <font color="blue">data from preclinical testing</font> and clinical     <font color="blue">trials may</font> be <font color="blue">different than</font> our <font color="blue">interpretation</font>;           •   failure of our <font color="blue">manufacturing</font> processes or <font color="blue">facilities</font> to <font color="blue">meet cGMP</font>     standards; and           •   changes in <font color="blue">approval policies</font> and <font color="blue">guidelines</font> or adoption of new     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The process of obtaining approvals to <font color="blue">manufacture</font> and market our products in     <font color="blue">foreign countries</font> is subject to delay and failure for similar reasons</td>
    </tr>
    <tr>
      <td>Even if we or our <font color="blue"><font color="blue">collaboration</font> partners</font> secure marketing approval for a     product, the <font color="blue">approval may</font> be conditioned, as is Xolair’s, on our successful     <font color="blue">completion</font> of post-marketing clinical studies or <font color="blue">may impose limitations on</font>     the <font color="blue">indicated uses</font> for which our <font color="blue">products may</font> be marketed</td>
    </tr>
    <tr>
      <td>In addition, each     <font color="blue">marketed product</font> and its <font color="blue">manufacture</font>r continue to be subject to strict     <font color="blue">conditions</font> and regulation after approval</td>
    </tr>
    <tr>
      <td>Any <font color="blue">unforeseen problems with</font> an     approved  product  or  any  violation  of  <font color="blue">regulations</font> could result in     <font color="blue">restrictions</font>  on  the  product, including, for example, changes in its     labeling, written notices to physicians or a <font color="blue">product recall</font></td>
    </tr>
    <tr>
      <td>An approval for     a  limited <font color="blue">indication</font> reduces the size of the <font color="blue">potential market</font> for the     product</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________    [50]Table of <font color="blue">Contents       </font>Delays in receiving or failing to receive <font color="blue"><font color="blue">regulatory</font> approvals</font>, or losing     <font color="blue">previously</font> received approvals to market Xolair, would delay or preclude     product  <font color="blue">commercialization</font>, which would <font color="blue"><font color="blue">adversely</font> affect</font> our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are subject to the <font color="blue">uncertainty</font> related to <font color="blue">reimbursement</font> policies and     <font color="blue">healthcare reform measures</font></td>
    </tr>
    <tr>
      <td>In recent years, there has <font color="blue">been legislation</font> and <font color="blue">numerous proposals</font> to change     the <font color="blue">healthcare system</font> in the US Some of these measures limit or eliminate     payments for medical procedures and <font color="blue">treatments</font> or subject <font color="blue">pharmaceutical</font>     product  pricing  to  <font color="blue">government</font>  control</td>
    </tr>
    <tr>
      <td>In addition, as a result of     marketplace pressures, third-party payors are <font color="blue">increasingly attempting</font> to     contain  healthcare  costs  <font color="blue">by limiting both coverage</font> and the level of     <font color="blue">reimbursement</font> of <font color="blue">new drug products</font></td>
    </tr>
    <tr>
      <td>Consequently, <font color="blue">significant</font> <font color="blue">uncertainty</font>     exists as to the <font color="blue">reimbursement</font> status of <font color="blue">newly approved healthcare products</font></td>
    </tr>
    <tr>
      <td>If we succeed in <font color="blue">bringing one</font> or more of our products to market, we cannot     assure you that third-party payors will consider them cost <font color="blue">effective</font> or     allow <font color="blue">reimbursement</font> to the <font color="blue">consumer at price levels sufficient</font> for us to     realize an <font color="blue">appropriate return on</font> our <font color="blue">investment</font> in product <font color="blue">development</font> or to     even realize a profit</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>changes in the <font color="blue">healthcare system</font> in the US or elsewhere,     including changes resulting from adverse trends in third-party <font color="blue">reimbursement</font>     programs, could <font color="blue">materially</font> reduce our potential <font color="blue">profitability</font> and harm our     ability to raise the capital we would need to continue our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Furthermore, any <font color="blue">decreases</font> in third-party <font color="blue">reimbursement</font> may <font color="blue">negatively</font>     affect our <font color="blue">collaborators</font>’ <font color="blue">commercialization</font> of Xolair, <font color="blue">which would also</font>     <font color="blue">adversely</font>  affect  our  business,  financial  condition and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>New <font color="blue">accounting pronouncements</font> or <font color="blue">regulatory</font> rulings may impact our future     <font color="blue">financial position</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>There may be new <font color="blue">accounting pronouncements</font> or <font color="blue">regulatory</font> rulings which may     have an <font color="blue">impact on</font> our future <font color="blue">financial position</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In     December 2004, the Financial Accounting Standards Board (“FASB”) issued a     revision of Statement of Financial Accounting Standards (or “FAS”) Nodtta 123,     “Accounting for Stock-Based Compensation</td>
    </tr>
    <tr>
      <td>” The revision is referred to as     “FAS 123R — Share-Based Payment” (or “FAS 123R”), which supersedes APB     Opinion Nodtta 25, “Accounting for Stock Issued to Employees,” (or “APB 25”)     and  will require companies to recognize <font color="blue">compensation expense</font>, using a     fair-value based method, for costs related to share-based payments including     <font color="blue">stock options</font> and <font color="blue">stock issued under employee stock</font> plans</td>
    </tr>
    <tr>
      <td>Tanox will adopt     FAS  123R using the <font color="blue">modified prospective basis on</font> January 1, 2006</td>
    </tr>
    <tr>
      <td>The     adoption of FAS 123R is expected to result in <font color="blue">compensation expense</font> that will     <font color="blue">reduce diluted net income per</font> share by approximately dlra0dtta13 to dlra0dtta16 per     share for 2006</td>
    </tr>
    <tr>
      <td>The actual 2006 stock <font color="blue">compensation expense</font> will <font color="blue">dependent on</font>     the number of options granted, employee turnover and the <font color="blue">volatility</font> of our     stock price</td>
    </tr>
    <tr>
      <td>Risks Relating to Our Industry, Business and Strategy        Our  ability to become a profitable <font color="blue">fully integrated</font> bio<font color="blue">pharmaceutical</font>     <font color="blue">company <font color="blue">will depend on</font></font> the <font color="blue">continued <font color="blue">commercial success</font></font> <font color="blue">of Xolair </font>and on the     success of our products in clinical <font color="blue">development</font> or our success in securing,     developing and <font color="blue">commercializing</font> new clinical <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We anticipate that, in the near term, our ability to <font color="blue">become profitable will</font>     depend  in  large part on the success of our <font color="blue"><font color="blue">collaboration</font> partners</font> in     <font color="blue">generating <font color="blue">significant</font> levels</font> of sales of Xolair</td>
    </tr>
    <tr>
      <td>In the longer term, an     important  part  of  our  strategy  is  to  become  a <font color="blue">fully integrated</font>     bio<font color="blue">pharmaceutical</font>  company</td>
    </tr>
    <tr>
      <td>Our  ability  to do so <font color="blue">will depend on</font> the     successful  <font color="blue">development</font>, approval and <font color="blue">commercialization</font> of TNX-355, of     TNX-832, or of potential new clinical-stage <font color="blue">drug <font color="blue">candidates</font></font> that we may     develop or otherwise in-license or acquire</td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________    [51]Table of <font color="blue">Contents       </font>All  of our <font color="blue">product candidate</font>s, other than TNX-355 and TNX-832, are in     preclinical  <font color="blue">development</font>  or in research, and we do not expect to seek     <font color="blue">regulatory</font>  approval  of  these  <font color="blue">candidates</font> for many years, if ever</td>
    </tr>
    <tr>
      <td>A     <font color="blue">significant</font> portion of the research that we are <font color="blue">conducting involves new</font> and     <font color="blue">unproven <font color="blue">technologies</font></font></td>
    </tr>
    <tr>
      <td>Research programs to identify <font color="blue">new disease targets</font> and     product  <font color="blue">candidates</font> require substantial technical, financial and human     <font color="blue">resources whether</font> or not we ultimately identify any <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Our research     programs  may  <font color="blue">show promise initially</font> in identifying <font color="blue">potential product</font>     <font color="blue">candidates</font>, yet fail to yield <font color="blue">product candidate</font>s for clinical <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>In addition, if we do not achieve the clinical <font color="blue">endpoints</font> in our clinical     studies of TNX-355 or TNX-832, we may decide to terminate <font color="blue">development</font> of     those products</td>
    </tr>
    <tr>
      <td>Even if we reach our <font color="blue">endpoints</font>, the results of the trials     may indicate that further <font color="blue">development</font> or <font color="blue">commercialization</font> of TNX-355 or     TNX-832 would not be <font color="blue">economically</font> viable</td>
    </tr>
    <tr>
      <td>In that event, we would need to     in-license or acquire suitable <font color="blue">product candidate</font>s or <font color="blue">products from third</font>     parties, and we may not be able to so for a number of reasons</td>
    </tr>
    <tr>
      <td>The licensing     and <font color="blue">acquisition</font> of <font color="blue">pharmaceutical</font> products is <font color="blue">highly competitive</font></td>
    </tr>
    <tr>
      <td>A number     of more <font color="blue">established companies</font>, including large <font color="blue">pharmaceutical</font> companies, are     <font color="blue">aggressively pursuing strategies</font> to license or acquire products in the     fields  in which we are interested</td>
    </tr>
    <tr>
      <td>These <font color="blue">established companies</font> have a     <font color="blue">competitive advantage over us due</font> to their size, cash and other resources,     and greater clinical <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">capabilities</font> and     experience</td>
    </tr>
    <tr>
      <td>Other factors that may <font color="blue">prevent us from</font> licensing or otherwise     acquiring suitable <font color="blue">product candidate</font>s include the following:           •   we may be unable to license or acquire the <font color="blue">relevant <font color="blue">technology</font> on</font>     terms that <font color="blue">would allow us</font> to make an <font color="blue">appropriate return from</font> the product;           •   companies that perceive us to be their <font color="blue"><font color="blue">competitors</font> may</font> be unwilling to     assign or license their <font color="blue">product rights</font> to us; or           •   we may be unable to identify <font color="blue">suitable products</font> or <font color="blue">product candidate</font>s     within our areas of expertise</td>
    </tr>
    <tr>
      <td>Even if we are successful in developing and <font color="blue">securing marketing approval</font> of     TNX-355, TNX-832 or other in-licensed or acquired <font color="blue">product candidate</font>s, we may     be unable to <font color="blue">successfully</font> launch, market or otherwise <font color="blue">commercialize</font> the     product</td>
    </tr>
    <tr>
      <td>If we are unable to secure suitable potential <font color="blue">product candidate</font>s through     <font color="blue">internal research programs</font> or by acquiring drugs or <font color="blue">drug <font color="blue">candidates</font></font> from     <font color="blue">third parties</font>, or if we are unable to <font color="blue">successfully</font> develop, launch, market     or <font color="blue">commercialize</font> the product(s), our goal of becoming a <font color="blue">fully integrated</font>     bio<font color="blue">pharmaceutical</font> company will not <font color="blue">materialize</font>, and our <font color="blue">profit potential</font>     will be harmed</td>
    </tr>
    <tr>
      <td>Failure to secure future <font color="blue"><font color="blue">collaboration</font> partners</font> for our products or failure     by  those partners to develop, <font color="blue">manufacture</font>, market or distribute those     products, or pay the royalties and other payments we expect, may delay or     <font color="blue">significant</font>ly impair our ability to <font color="blue">generate revenues</font> or profit</td>
    </tr>
    <tr>
      <td>We intend to rely on future <font color="blue"><font color="blue">collaboration</font> partners</font> to develop, <font color="blue">manufacture</font>,     <font color="blue">commercialize</font>, market or <font color="blue">distribute certain</font> of our <font color="blue">product candidate</font>s, both     to <font color="blue">allocate financial risk</font> and to secure the expertise that those partners     may have in one or more of the <font color="blue">foregoing areas</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> are     similarly seeking to develop or expand their <font color="blue">collaboration</font> and license     <font color="blue"><font color="blue">arrangements</font> with</font> <font color="blue">pharmaceutical</font> companies</td>
    </tr>
    <tr>
      <td>The success of these <font color="blue">efforts by</font>     our <font color="blue">competitors</font> could have an adverse <font color="blue">impact on</font> our ability to form future     <font color="blue">collaboration</font> <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>Also, the <font color="blue">pharmaceutical</font> companies that we may     target for one or more of our <font color="blue">product candidate</font>s might require a profit     return that is greater than what our product may be able to deliver</td>
    </tr>
    <tr>
      <td>The     process of <font color="blue">establishing collaborative <font color="blue">relationship</font>s</font> is <font color="blue">difficult</font> and time     consuming and involves <font color="blue">significant</font> <font color="blue">uncertainty</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we     will be able to negotiate acceptable <font color="blue">collaboration</font> <font color="blue">agreements</font> in the future</td>
    </tr>
    <tr>
      <td>To  the  extent  that we are unable to enter into future <font color="blue">collaboration</font>     <font color="blue">agreements</font>, we would encounter increased capital <font color="blue"><font color="blue">requirement</font>s</font> to undertake     research, <font color="blue">development</font> and <font color="blue">marketing at</font> our own expense, and, in some cases,     may have to discontinue <font color="blue">development</font> of one or more products</td>
    </tr>
    <tr>
      <td>Assuming we are     able to continue to develop <font color="blue">certain <font color="blue">products on</font></font>                                           21     ______________________________________________________________________    [52]Table of <font color="blue">Contents       </font>our own, we may experience <font color="blue">significant</font> delays in introducing our product     <font color="blue">candidates</font>  or find that the absence of these <font color="blue">collaboration</font> <font color="blue">agreements</font>     <font color="blue"><font color="blue">adversely</font> affect</font>s our ability to <font color="blue">manufacture</font> or sell our <font color="blue">product candidate</font>s,     <font color="blue"><font color="blue">particularly</font> outside</font> the US       Even if we enter into future collaborative <font color="blue">agreements</font>, we <font color="blue">cannot assure</font> you     that <font color="blue">efforts under</font> these <font color="blue">agreements</font> will succeed because:           •   the <font color="blue">contracts may fail</font> to provide <font color="blue">significant</font> protection or may become     unenforceable if the <font color="blue">partners fail</font> to perform;           •   our <font color="blue">partners may</font> not <font color="blue">commit enough capital</font> or other resources to     <font color="blue">successfully</font> develop, market or distribute our products;           •   our <font color="blue">partners may</font> not continue to develop and <font color="blue">commercialize</font> products     resulting from our <font color="blue">collaboration</font>s; and           •   <font color="blue">disputes with</font> our <font color="blue">partners may</font> arise that <font color="blue">could delay</font> or terminate our     <font color="blue">product candidate</font>s’ research, <font color="blue">development</font> or <font color="blue">commercialization</font> or result in     <font color="blue">significant</font> <font color="blue">litigation</font> or <font color="blue">arbitration</font></td>
    </tr>
    <tr>
      <td>If any of these <font color="blue">contingencies</font> occur, our revenues, results of <font color="blue">operations</font>,     product <font color="blue">development</font>, productivity and business may suffer</td>
    </tr>
    <tr>
      <td>We face intense <font color="blue">competition</font> and rapid <font color="blue">technological</font> change that could result     in products superior to the products we are developing</td>
    </tr>
    <tr>
      <td>The <font color="blue">bio<font color="blue">technology</font></font> and <font color="blue"><font color="blue">pharmaceutical</font> industries</font> are subject to rapid and     <font color="blue">significant</font> <font color="blue">technological</font> change</td>
    </tr>
    <tr>
      <td>We have numerous <font color="blue">competitors</font> in the US     and abroad, including, among others, major <font color="blue">pharmaceutical</font> and chemical     companies, specialized <font color="blue">bio<font color="blue">technology</font></font> firms, <font color="blue">universities</font> and other research     <font color="blue">institutions</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">competitors</font> may</font> develop <font color="blue">technologies</font> and products that     are more <font color="blue">effective</font> or <font color="blue">less costly than</font>, or <font color="blue">otherwise preferable</font> to, any of     our current or <font color="blue">future products</font>, and that could render our <font color="blue">technologies</font> and     products  obsolete  or  <font color="blue">noncompetitive</font></td>
    </tr>
    <tr>
      <td>Many of these <font color="blue">competitors</font> have     <font color="blue">substantially</font>  more  resources and product <font color="blue">development</font>, production and     marketing <font color="blue">capabilities</font> than we do</td>
    </tr>
    <tr>
      <td>We cannot be certain that one or more     <font color="blue">companies will</font> not receive <font color="blue">patent protection</font> that dominates, blocks or     otherwise  <font color="blue">adversely</font>  affects  our product <font color="blue">development</font> or business</td>
    </tr>
    <tr>
      <td>In     addition, many of our <font color="blue">competitors</font> have <font color="blue">significant</font>ly greater experience than     we  do  in  undertaking  preclinical  testing  and  <font color="blue"><font color="blue">clinical trial</font>s</font> of     <font color="blue">pharmaceutical</font> products and obtaining FDA and other <font color="blue"><font color="blue">regulatory</font> approvals</font> of     products</td>
    </tr>
    <tr>
      <td>If we succeed in achieving <font color="blue">commercial sales</font> of our products, we     also will be competing in commercial <font color="blue">manufacturing</font> efficiency and marketing     capability, areas in which we have no experience</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitors</font> may</font> obtain     FDA approval for <font color="blue">products sooner</font> or be more successful in <font color="blue">manufacturing</font> and     marketing their <font color="blue">products than</font> are we or our <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>Xolair competes, and our <font color="blue">drug <font color="blue">candidates</font></font> that are <font color="blue">successfully</font> developed and     approved for marketing will compete, with numerous existing therapies, as     well as a <font color="blue">significant</font> number of drugs that are currently under <font color="blue">development</font>     and  <font color="blue">will become available</font> in the future for the treatment of allergic     asthma, HIV and other <font color="blue">diseases targeted by</font> our <font color="blue">product candidate</font>s</td>
    </tr>
    <tr>
      <td>The     introduction of new products or follow-on biologics or new information about     existing <font color="blue">products may</font> result in lost market share or <font color="blue">lower prices</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">collaborators</font>’ abilities to <font color="blue">successfully</font> market Xolair or expand its usage     and our ability to bring new products to the marketplace and <font color="blue">successfully</font>     compete for <font color="blue">market <font color="blue">acceptance</font></font> and market share among physicians, patients,     <font color="blue">healthcare payors</font> and the medical <font color="blue">community</font>, <font color="blue">will depend on</font> many factors:           •   <font color="blue">relative efficacy</font> and safety of our products;           •   timing and scope of <font color="blue">regulatory</font> approval;                                           22     ______________________________________________________________________    [53]Table of <font color="blue">Contents       </font>  •   <font color="blue">product <font color="blue">availability</font></font>;           •   potential advantages over alternative treatment methods;           •   <font color="blue">development</font>, marketing, <font color="blue">distribution</font> and <font color="blue">manufacturing</font> <font color="blue">capabilities</font>     and support of our <font color="blue">collaborators</font>, if any;           •   <font color="blue">reimbursement</font> coverage from Medicare/Medicaid, <font color="blue">insurance companies</font> and     others;           •   price and cost-<font color="blue">effective</font>ness of our products;           •   ability to produce <font color="blue">drug <font color="blue">candidates</font></font> in <font color="blue"><font color="blue">commercial quantities</font> at</font> a     <font color="blue">reasonable cost</font>;           •   scope of <font color="blue">patent protection</font> for our products; and           •   <font color="blue">availability</font> of <font color="blue">licenses under third party <font color="blue">technology</font></font> and patent     rights</td>
    </tr>
    <tr>
      <td>For instance, in mid-October 2005, Critical Therapeutics, Inc</td>
    </tr>
    <tr>
      <td>launched     Zyflo for the prevention and <font color="blue">chronic treatment</font> of asthma in patients 12     years  of  age  and older</td>
    </tr>
    <tr>
      <td>While not a <font color="blue">direct competitor</font> to Xolair, we     understand that Critical Therapeutics’ <font color="blue">marketing efforts</font> are <font color="blue">directed at</font> the     use of Zyflo prior to Xolair</td>
    </tr>
    <tr>
      <td>We are also aware of other <font color="blue">asthma therapies</font>     that <font color="blue">may compete with</font> Xolair</td>
    </tr>
    <tr>
      <td>If our products are not <font color="blue">competitive based on</font> the foregoing or other factors,     our  business,  financial  condition and results of <font color="blue">operations</font> will be     <font color="blue">materially</font> harmed</td>
    </tr>
    <tr>
      <td>We may be unable to attract and retain <font color="blue">key personnel</font> and <font color="blue">principal members</font>     of our scientific and <font color="blue">management staff</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">success depends</font> greatly on</font> our ability to attract and retain qualified     scientific, <font color="blue">manufacturing</font>, clinical and other <font color="blue">technical personnel</font>, as well     as to retain the services of our existing technical <font color="blue">management staff</font></td>
    </tr>
    <tr>
      <td>To     pursue our research and <font color="blue">development</font> programs and product <font color="blue">development</font> plans,     we will be required to hire <font color="blue">additional</font> qualified clinical, scientific,     <font color="blue">manufacturing</font>,  QA/QC  and other <font color="blue">technical personnel</font></td>
    </tr>
    <tr>
      <td>There is intense     <font color="blue">competition</font> for <font color="blue">qualified staff</font>, and we <font color="blue">cannot assure</font> you that we will be     able to attract and retain the <font color="blue">necessary</font> <font color="blue">qualified staff</font> to develop our     business</td>
    </tr>
    <tr>
      <td>The  failure  to attract and retain these <font color="blue">key personnel</font> and     <font color="blue">management staff</font>, or the loss of any of our <font color="blue">current management team</font> and our     <font color="blue">inability</font> to <font color="blue">replace him</font> or her on a <font color="blue">timely basis</font>, could <font color="blue">materially</font> harm our     business and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We may be subject to <font color="blue">product liability</font> and other claims, and our insurance     coverage may not be adequate to cover these claims</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">exposes us</font> to <font color="blue">potential product</font> liability risks, which are     inherent in testing, <font color="blue">manufacturing</font>, marketing and selling <font color="blue">pharmaceutical</font>     products</td>
    </tr>
    <tr>
      <td>We may be held liable if any product we develop, or any product     that uses or <font color="blue">incorporates</font> any of our <font color="blue">technologies</font>, causes side effects,     injury  or  is  found  otherwise  unsuitable  <font color="blue">during clinical testing</font>,     <font color="blue">manufacturing</font>, marketing or sale</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be able     to avoid <font color="blue">product liability</font> exposure</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability insurance</font> for the bio<font color="blue">pharmaceutical</font> industry is <font color="blue">generally</font>     expensive</td>
    </tr>
    <tr>
      <td>Although we currently maintain <font color="blue">product liability</font> insurance     covering our products in amounts we believe to be <font color="blue">commercially</font> reasonable,     we  cannot  assure you that our coverage is adequate or that continued     <font color="blue">coverage will</font> be <font color="blue">available at</font> acceptable costs</td>
    </tr>
    <tr>
      <td>In addition, some of our     license and <font color="blue">collaboration</font> <font color="blue">agreements</font> require us to obtain <font color="blue">product liability</font>     insurance</td>
    </tr>
    <tr>
      <td>Future license and <font color="blue">collaboration</font> <font color="blue">agreements</font> may also                                           23     ______________________________________________________________________    [54]Table of <font color="blue">Contents       </font>include such a <font color="blue">requirement</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to obtain <font color="blue">sufficient insurance</font>     <font color="blue">coverage at</font> an acceptable cost or otherwise to <font color="blue">protect against potential</font>     <font color="blue">product liability</font> claims <font color="blue">could prevent</font> or <font color="blue">inhibit us</font> or our <font color="blue">collaborators</font>     from <font color="blue">commercializing</font> our products</td>
    </tr>
    <tr>
      <td>A successful claim in excess of our     insurance coverage could <font color="blue">materially</font> harm our business, <font color="blue">financial condition</font>     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, any such claim could <font color="blue">materially</font>     reduce our <font color="blue">future revenues from sales</font> of those products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">insurance coverage may</font> not be adequate to cover other claims and losses     resulting from operating, <font color="blue">manufacturing</font> and business hazards, including     <font color="blue">natural disasters</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">deal with <font color="blue"><font color="blue">hazardous</font> materials</font></font> and <font color="blue">must comply with <font color="blue">environmental laws</font></font> and     <font color="blue">regulations</font>, which can be expensive and <font color="blue">restrict how</font> we do business</td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> work and <font color="blue">manufacturing</font> processes involve the     <font color="blue">controlled use</font> of <font color="blue"><font color="blue">hazardous</font> materials</font>, including chemical, radioactive and     <font color="blue">biological materials</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> also produce <font color="blue"><font color="blue">hazardous</font> waste products</font></td>
    </tr>
    <tr>
      <td>We are subject to federal, state and <font color="blue">local laws</font> and <font color="blue">regulations</font> governing     how we use, <font color="blue">manufacture</font>, store, handle and dispose of these materials</td>
    </tr>
    <tr>
      <td>Although we believe that we comply in all material <font color="blue">respects with applicable</font>     <font color="blue">environmental laws</font> and <font color="blue">regulations</font>, we <font color="blue">cannot assure</font> you that we will not     incur <font color="blue">significant</font> costs to comply with <font color="blue">environmental laws</font> and <font color="blue">regulations</font> in     the  future</td>
    </tr>
    <tr>
      <td>In  addition,  current  or future <font color="blue">environmental laws</font> and     <font color="blue">regulations</font> may impair our research, <font color="blue">development</font> or <font color="blue">production efforts</font></td>
    </tr>
    <tr>
      <td>We could be liable for damages, penalties or other forms of censure if we     are involved in a <font color="blue"><font color="blue">hazardous</font> waste spill</font> or other <font color="blue">accident</font></td>
    </tr>
    <tr>
      <td><font color="blue">Despite  </font><font color="blue">precautionary</font>  procedures  that we implement for handling and     disposing of <font color="blue"><font color="blue">hazardous</font> materials</font>, we <font color="blue">cannot eliminate</font> the risk of <font color="blue">accident</font>al     <font color="blue">contamination</font> or discharge or any <font color="blue">resultant injury from</font> these materials</td>
    </tr>
    <tr>
      <td>If     a <font color="blue"><font color="blue">hazardous</font> waste spill</font> or other <font color="blue">accident</font> occurs, and we are held liable for     damages, the <font color="blue">liability could exceed</font> our <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Associated </font>with <font color="blue">Manufacturing </font>and Marketing        Our revenues are <font color="blue">dependent on</font> the continued <font color="blue">market <font color="blue">acceptance</font></font> and successful     <font color="blue">commercialization</font> of Xolair</td>
    </tr>
    <tr>
      <td>Our results of <font color="blue">operations</font> and <font color="blue">future prospects</font> are highly <font color="blue">dependent on</font>     increasing the sales of our <font color="blue">only commercial product</font>, Xolair</td>
    </tr>
    <tr>
      <td>Our revenues in     2005 consisted largely of revenue relating to sales of Xolair, and we expect     that revenues from sales <font color="blue">of Xolair </font>and from payments based on the quantity     <font color="blue">of Xolair </font><font color="blue">manufacture</font>d will constitute a <font color="blue">larger percentage</font> of our revenue in     the <font color="blue">next several years</font></td>
    </tr>
    <tr>
      <td>Even <font color="blue">though initial insurance</font> and Medicare/Medicaid     coverage <font color="blue">of Xolair </font>is <font color="blue">encouraging</font>, we cannot be certain that physicians,     patients and <font color="blue">payors will continue</font> to <font color="blue">widely accept</font> Xolair as a treatment for     its approved <font color="blue">indication</font> in the US or in any <font color="blue">foreign markets</font></td>
    </tr>
    <tr>
      <td>A number of     factors  may  affect  the  rate  and level of Xolair’s <font color="blue">ultimate market</font>     <font color="blue">acceptance</font>, including:           •   the <font color="blue">effective</font>ness of Novartis’ and Genentech’s sales and marketing     efforts;           •   the <font color="blue">perception by physicians</font> and other members of the healthcare     <font color="blue">community</font> of Xolair’s safety, efficacy and <font color="blue">benefits compared</font> to those of     <font color="blue">competing products</font> or therapies;           •   the <font color="blue">willingness</font> of <font color="blue"><font color="blue">additional</font> physicians</font> to adopt a new asthma     <font color="blue">treatment regimen</font>;           •   Xolair’s <font color="blue">price relative</font> to other products or competing <font color="blue">treatments</font>;           •   the <font color="blue">availability</font> of third-party <font color="blue">reimbursement</font>;                                           24     ______________________________________________________________________    [55]Table of <font color="blue">Contents       </font>  •   the ability to conduct <font color="blue">the Xolair </font><font color="blue">post marketing commitment studies</font>     and the impact of the study results on the labeling of Xolair;           •   the ability to secure marketing approval <font color="blue">for Xolair </font>in Asia;           •   <font color="blue">regulatory</font> <font color="blue">development</font>s related to <font color="blue">manufacturing</font> or using Xolair;           •   the results of clinical <font color="blue">development</font> efforts for potential new     <font color="blue">indication</font>s for Xolair, and the scope and timing of <font color="blue"><font color="blue">additional</font> marketing</font>     approvals and favorable <font color="blue">reimbursement</font> programs for any <font color="blue">such expanded use</font>;           •   <font color="blue">availability</font> of <font color="blue">sufficient quantities</font> <font color="blue">of Xolair </font>for commercial and     clinical purposes;           •   increased <font color="blue">competition</font> <font color="blue">for Xolair </font>from new or existing products, which     may <font color="blue">demonstrate</font> better safety, efficacy, cost-<font color="blue">effective</font>ness or ease of     <font color="blue">administration than</font> Xolair; and           •   adverse side effects or unfavorable publicity <font color="blue">concerning</font> Xolair</td>
    </tr>
    <tr>
      <td>If the level <font color="blue">of Xolair </font><font color="blue">sales declines</font> or fails to increase, our financial     condition, results of <font color="blue">operations</font> and <font color="blue">future potential would</font> be <font color="blue">significant</font>ly     harmed</td>
    </tr>
    <tr>
      <td>We have limited experience in <font color="blue">manufacturing</font>, and <font color="blue">manufacturing</font> problems or     <font color="blue">delays could</font> result in delayed <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing </font>bio<font color="blue">pharmaceutical</font>s is <font color="blue">difficult</font> and complex, and requires     <font color="blue">facilities</font> specifically designed and validated for this purpose</td>
    </tr>
    <tr>
      <td>It can take     years to design, construct, validate, and license a new bio<font color="blue">pharmaceutical</font>     <font color="blue">manufacturing</font> <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>To  develop  products,  we  require <font color="blue">sufficient quantity</font> and quality of     <font color="blue">manufacture</font>d  product  for  clinical  trials</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font>or technical     <font color="blue">manufacturing</font> issues that we may encounter <font color="blue">could delay</font> clinical <font color="blue">development</font>     of our products</td>
    </tr>
    <tr>
      <td>Any failure to produce these clinical <font color="blue"><font color="blue">requirement</font>s</font>, either     as a result of our <font color="blue">inability</font> to produce in <font color="blue"><font color="blue">accordance</font> with cGMP</font> or due to     inadequate  <font color="blue">manufacturing</font>  <font color="blue">capacity</font>,  can  delay  the  <font color="blue">commencement</font> or     <font color="blue">continuation</font> of our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We own a pilot <font color="blue">manufacturing</font> <font color="blue">facility</font>     in Houston, Texas, and, in January 2005, we assumed the long-term lease on,     and purchased <font color="blue">manufacturing</font> equipment with respect to, a <font color="blue">manufacturing</font>     <font color="blue">facility</font> with two 2cmam750L bioreactors in San Diego, California</td>
    </tr>
    <tr>
      <td>We secured     the <font color="blue">facility</font> in San Diego with the intent of <font color="blue">manufacturing</font> <font color="blue">clinical trial</font>     materials and <font color="blue"><font color="blue">potentially</font> initial commercial launch products</font>, and we have     been working to re-commission the <font color="blue">facility</font> for the cGMP <font color="blue">manufacture</font> of <font color="blue">Phase     </font>3 supplies of TNX-355</td>
    </tr>
    <tr>
      <td>The <font color="blue">facility</font> was built in 1992 and had <font color="blue">been idled by</font>     <font color="blue">Biogen Idec </font>for at least a year prior to our <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>While we believe     that the majority of the <font color="blue">issues associated with</font> the re-commissioning have     been  resolved, we may have problems that may delay or <font color="blue">prevent us from</font>     <font color="blue">manufacturing</font> the <font color="blue">clinical supplies</font> of TNX-355 we need for Phase 3</td>
    </tr>
    <tr>
      <td>If we     are unable to <font color="blue">manufacture</font> the required <font color="blue">supplies ourselves</font>, we may have to     pursue contract <font color="blue">manufacturing</font>, which would result in a <font color="blue">significant</font> delay and     increase in cost of the <font color="blue">development</font> program</td>
    </tr>
    <tr>
      <td>Our own ability to <font color="blue">manufacture</font> <font color="blue">products on</font> a <font color="blue">commercial scale</font> is uncertain</td>
    </tr>
    <tr>
      <td>To <font color="blue">commercialize</font> our products <font color="blue">successfully</font>, we must <font color="blue">manufacture</font> our products     in <font color="blue">commercial quantities</font> in compliance with <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> and at     an acceptable cost</td>
    </tr>
    <tr>
      <td>If the <font color="blue">manufacturing</font> <font color="blue">facilities</font> used to produce our     products cannot pass pre-approval or periodic plant <font color="blue">inspections</font>, the FDA and     other <font color="blue"><font color="blue">regulatory</font> agencies</font> may not approve our products for sale or may delay     or bar their further sale</td>
    </tr>
    <tr>
      <td>In order to obtain <font color="blue"><font color="blue">regulatory</font> approvals</font> and to     create  <font color="blue">capacity</font>  to produce our products in <font color="blue">sufficient quantities</font> for     <font color="blue">commercial sale at</font> an acceptable cost, we will have to develop or acquire     <font color="blue">additional</font>  <font color="blue">technology</font> for <font color="blue">commercial scale</font> <font color="blue">manufacturing</font> and build or     otherwise obtain access to adequate <font color="blue">facilities</font>                                           25     ______________________________________________________________________    [56]Table of <font color="blue">Contents       </font>such as contract <font color="blue">manufacturing</font> organizations, which will require substantial     <font color="blue">additional</font> funds</td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">manufacture</font>rs of bio<font color="blue">pharmaceutical</font> products     often encounter <font color="blue">difficult</font>ies in <font color="blue">scaling up production</font>, including problems     involving production yields, quality control and assurance, shortage of     qualified personnel, compliance with FDA <font color="blue">regulations</font>, production costs,     <font color="blue">demonstration</font> of the ability to <font color="blue">manufacture</font> the <font color="blue">product using controlled</font>,     <font color="blue">reproducible processes</font>, and <font color="blue">development</font> of advanced <font color="blue">manufacturing</font> <font color="blue">techniques</font>     and <font color="blue">process controls</font></td>
    </tr>
    <tr>
      <td>To the extent we utilize contract <font color="blue">manufacture</font>rs, we     must  rely  on  them to perform in <font color="blue">accordance</font> with the contract terms</td>
    </tr>
    <tr>
      <td>Furthermore, because of the size of the dose of TNX-355 that may be required     to see a <font color="blue">therapeutic</font> benefit, it may be <font color="blue">difficult</font> for us to find one or more     <font color="blue">contractors</font> who have the expertise and <font color="blue">facilities</font> to produce bulk drug     substance of TNX-355 in <font color="blue">commercial quantities</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we,     operating alone or with the assistance of others, can develop the <font color="blue">necessary</font>     <font color="blue">manufacturing</font>  <font color="blue">technology</font>  or that we will be able to fund or build an     adequate commercial <font color="blue">manufacturing</font> <font color="blue">facility</font> <font color="blue">necessary</font> to obtain <font color="blue">regulatory</font>     approvals and to produce <font color="blue">adequate commercial supplies</font> of our potential     <font color="blue">products on</font> a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>We also must rely on third-party contract <font color="blue">manufacture</font>rs to fill and finish     and label and package our product for <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font>     that we will be able to secure these <font color="blue">services on</font> a <font color="blue">timely basis</font> or that the     <font color="blue">services will</font> be performed in a manner that passes our <font color="blue">quality assurance</font>     standards</td>
    </tr>
    <tr>
      <td>Any failure or <font color="blue">delay by</font> these <font color="blue">third parties</font> <font color="blue">could delay</font> our     filing for an IND or impede the progress of a <font color="blue">clinical trial</font> and would     increase our <font color="blue">development</font> costs</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing </font>changes may result in delays in obtaining <font color="blue">regulatory</font> approval     or marketing for our products</td>
    </tr>
    <tr>
      <td>If we make any changes in the <font color="blue">manufacturing</font> process for our products and     <font color="blue">product candidate</font>s once we begin clinical <font color="blue">development</font>, we may be required to     <font color="blue">demonstrate</font>  to the FDA and <font color="blue">corresponding</font> foreign <font color="blue">authorities</font> that the     changes have not caused the resulting drug material to differ <font color="blue">significant</font>ly     from the drug material <font color="blue">previously</font> produced</td>
    </tr>
    <tr>
      <td>Any <font color="blue">significant</font> <font color="blue">manufacturing</font>     changes for the production of our <font color="blue">product candidate</font>s could result in delays     in <font color="blue">development</font> or <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td><font color="blue">Changing  </font>the  <font color="blue">manufacturing</font>  site is considered to be a change in the     <font color="blue">manufacturing</font> process; therefore, moving TNX-355 production to our <font color="blue">San Diego     </font><font color="blue">manufacturing</font> <font color="blue">facility</font> from our Houston pilot plant entailed <font color="blue">manufacturing</font>     changes</td>
    </tr>
    <tr>
      <td>In addition, we made other changes to the TNX-355 <font color="blue">manufacturing</font>     process to increase cell-line yield</td>
    </tr>
    <tr>
      <td>Accordingly, we will need to show that     the drug material we produce in the San Diego <font color="blue">manufacturing</font> <font color="blue">facility</font> for the     Phase 3 studies is <font color="blue">sufficiently</font> similar to the product that was used for the     Phase 2 study in order to <font color="blue">avoid delays</font> in <font color="blue">development</font> or <font color="blue">regulatory</font> approval     for this <font color="blue">antibody product</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">demonstrate</font> comparability     between the material we produce before and after <font color="blue">manufacturing</font> changes, we     may not be able to rely on the results of <font color="blue">prior preclinical studies</font> and     <font color="blue"><font color="blue">clinical trial</font>s</font> performed using the <font color="blue">previously</font> produced drug material</td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font>upon the type and degree of <font color="blue">differences between</font> the newer and     <font color="blue">older drug</font> material, we may be required to conduct <font color="blue">additional</font> animal studies     or  human  <font color="blue"><font color="blue">clinical trial</font>s</font> to <font color="blue">demonstrate</font> that the newly produced drug     material is <font color="blue">sufficiently</font> similar to the <font color="blue">previously</font> produced drug material</td>
    </tr>
    <tr>
      <td>We may make <font color="blue">manufacturing</font> changes for the production of TNX-832, our other     product  currently  in clinical <font color="blue">development</font>, as well as future product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>An <font color="blue">inability</font> to <font color="blue">show comparability between</font> the older material     and the newer material after making <font color="blue">manufacturing</font> changes could result in     <font color="blue">significant</font> delays in <font color="blue">development</font> or <font color="blue"><font color="blue">regulatory</font> approvals</font> of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">lack sales</font> and marketing experience, and we depend on <font color="blue">third parties</font> for     their expertise in this area</td>
    </tr>
    <tr>
      <td>Under the terms of our <font color="blue">collaboration</font> <font color="blue">agreements</font>, <font color="blue">Novartis and <font color="blue">Genentech </font></font>have     exclusive  <font color="blue">marketing rights</font> to Xolair and other <font color="blue">collaboration</font> anti-IgE     products, and the revenues we receive from Xolair <font color="blue">will depend primarily on</font>     the marketing and <font color="blue">sales efforts</font> of our <font color="blue"><font color="blue">collaboration</font> partners</font></td>
    </tr>
    <tr>
      <td>However,     <font color="blue">commercialization</font>  rights  may  revert back to us if our <font color="blue">collaborators</font>     terminate our <font color="blue">relationship</font></td>
    </tr>
    <tr>
      <td>Furthermore, we may retain <font color="blue">marketing rights</font>,     <font color="blue">particularly</font> in the US and selected Asian countries, for                                           26     ______________________________________________________________________    [57]Table of <font color="blue">Contents       </font>other <font color="blue">potential product</font>s that we can develop and sell <font color="blue"><font color="blue">effective</font>ly</font> with a     small, targeted <font color="blue">sales force</font></td>
    </tr>
    <tr>
      <td>We have not yet <font color="blue">commercialize</font>d any of our     internal or in-licensed <font color="blue">product candidate</font>s, and we currently have no sales,     marketing or <font color="blue">distribution</font> <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercialization</font> of products     that may be approved for marketing is subject to <font color="blue">several risks</font>, including     but not limited to: <font color="blue">difficult</font>ies in <font color="blue">manufacturing</font> the <font color="blue">product on</font> a large     scale; <font color="blue">difficult</font>ies in planning, <font color="blue">coordinating</font> and executing the commercial     launch of the product; <font color="blue">difficult</font>ies in marketing, <font color="blue">distribution</font> or sale of     the product; <font color="blue">competition</font> from superior products; or <font color="blue">third party patents</font> that     <font color="blue">may preclude us from marketing</font> the product</td>
    </tr>
    <tr>
      <td>If Xolair <font color="blue">marketing rights</font> revert to us or if we elect to market other     products  directly, we would require <font color="blue">significant</font> <font color="blue">additional</font> management     expertise and have to make <font color="blue">significant</font> <font color="blue">additional</font> <font color="blue">expenditures</font> to develop an     <font color="blue">internal marketing function</font> and a <font color="blue">sales force</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we     would be able to establish a <font color="blue">successful marketing</font> and <font color="blue">sales force</font> should we     choose to do so</td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in hiring and retaining sales and     <font color="blue">marketing personnel with appropriate technical</font> and <font color="blue">sales expertise</font> or in     developing an <font color="blue">adequate <font color="blue">distribution</font>s capability</font> to <font color="blue">support them</font>, our ability     to <font color="blue">generate product revenues will</font> be <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>To the extent we     cannot or choose not to use internal resources for the marketing, sales or     <font color="blue">distribution</font> of any <font color="blue">potential product</font>s in the US or elsewhere, we intend     to  rely on <font color="blue"><font color="blue">collaboration</font> partners</font> or licensees</td>
    </tr>
    <tr>
      <td>We may not be able to     establish or maintain such <font color="blue">relationship</font>s or, if we are able to establish     them, we <font color="blue">will depend upon</font> their efforts, which may not be successful</td>
    </tr>
    <tr>
      <td>Risks Related to Financial Results and Need for Financing        We have a history of net losses; we expect to continue to <font color="blue">incur net losses</font>     and we may never achieve or maintain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">incurred net losses since</font> our inception</td>
    </tr>
    <tr>
      <td><font color="blue">As of December </font>31, 2005, we     had an <font color="blue">accumulated deficit</font> of approximately dlra113dtta3 million, including a net     loss of dlra19dtta4 million for 2005</td>
    </tr>
    <tr>
      <td>Our <font color="blue">losses primarily</font> have been the result of     <font color="blue">costs incurred</font> in our research and <font color="blue">development</font> programs and from our general     and <font color="blue">administrative costs</font></td>
    </tr>
    <tr>
      <td>We have funded our <font color="blue">operations</font> to <font color="blue">date principally from licensing fees</font>,     royalties, profit-sharing, milestone and <font color="blue">manufacturing</font>-rights payments under     our current or former <font color="blue">collaboration</font>s, as well as with proceeds from private     <font color="blue">placements</font> and an <font color="blue">initial public offering</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We expect to     continue to incur substantial operating <font color="blue">losses until such</font> time, if ever,     that we are able to generate sufficient <font color="blue">revenue from</font> royalties, profit     sharing, and <font color="blue">manufacturing</font> rights from Xolair and, <font color="blue">potentially</font>, revenues     from an <font color="blue">additional</font> product or products to cover our expenses</td>
    </tr>
    <tr>
      <td>Our revenues     may be reduced by <font color="blue">adjustments</font> and changes in <font color="blue">amounts paid</font> to us and amounts     we may be required to pay to <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Our ability to achieve and maintain long-term <font color="blue">profitability</font> depends to a     <font color="blue">significant</font> extent on the continued successful <font color="blue">commercialization</font> of Xolair</td>
    </tr>
    <tr>
      <td>It <font color="blue">will also depend on</font> our <font color="blue">successfully</font> completing preclinical and clinical     trials,  obtaining  required  <font color="blue">regulatory</font>  approvals  and  <font color="blue">successfully</font>     <font color="blue">manufacturing</font> and marketing our other current and future <font color="blue">product candidate</font>s</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be able to achieve any of the foregoing or     that  we  will be <font color="blue">profitable even</font> if we <font color="blue">successfully</font> <font color="blue">commercialize</font> our     products</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> has <font color="blue">been volatile</font></td>
    </tr>
    <tr>
      <td>Like other stocks of bio<font color="blue">pharmaceutical</font> companies, the <font color="blue">market price</font> for our     <font color="blue">common stock</font> has been and may continue to be volatile</td>
    </tr>
    <tr>
      <td><font color="blue">Since January </font>1,     2004, our stock price ranged from dlra9dtta39 to dlra19dtta75</td>
    </tr>
    <tr>
      <td>Factors that may have     <font color="blue">contributed</font> to the <font color="blue">volatility</font> of our <font color="blue">stock during</font> this period included:           •   Reported <font color="blue">sales volume</font> of Xolair;           •   Results of <font color="blue"><font color="blue">clinical trial</font>s</font>; and           •   General market <font color="blue">conditions</font>, including <font color="blue">particularly</font> the <font color="blue">bio<font color="blue">technology</font></font>     company segment</td>
    </tr>
    <tr>
      <td>27     ______________________________________________________________________    [58]Table of <font color="blue">Contents       </font>Other factors that may have a <font color="blue">significant</font> <font color="blue">impact on</font> the <font color="blue">market price</font> of our     common Stock include:           •   <font color="blue">Announcements </font>of <font color="blue">technological</font> <font color="blue">innovations</font> by us or our <font color="blue">competitors</font>;           •   <font color="blue">Publicity </font>regarding actual or <font color="blue">potential medical</font> results relating to     Xolair or products being developed by us;           •   <font color="blue">Potential </font><font color="blue">litigation</font> or material contracts to which we may be a party;           •   <font color="blue">Regulatory </font><font color="blue">development</font>s or delays <font color="blue">concerning</font> our products; and           •   Issues <font color="blue">concerning</font> the safety or <font color="blue">commercial viability</font> of our products</td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>by  <font color="blue">Novartis  </font>or <font color="blue">Genentech </font>to develop, <font color="blue">manufacture</font>, market or     distribute Xolair <font color="blue">would impair</font> our ability to <font color="blue">generate revenues</font></td>
    </tr>
    <tr>
      <td>Under the terms of our <font color="blue">collaboration</font> <font color="blue">agreements</font>, <font color="blue">Novartis and <font color="blue">Genentech </font></font>are     <font color="blue">generally</font>  responsible  for  conducting  <font color="blue"><font color="blue">clinical trial</font>s</font> on, obtaining     <font color="blue">regulatory</font> approval for, and <font color="blue">manufacturing</font>, marketing and <font color="blue">distributing</font>     Xolair</td>
    </tr>
    <tr>
      <td>As  a result, our ability to profit from Xolair and any other     anti-IgE products covered by our <font color="blue">collaboration</font> <font color="blue">agreements</font> with <font color="blue">Genentech </font>and     Novartis depends in large part on their performance</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot control</font> the     amount and timing of resources <font color="blue">Novartis and <font color="blue">Genentech </font></font><font color="blue">will devote</font> to any of     our  products</td>
    </tr>
    <tr>
      <td>If  Novartis or <font color="blue">Genentech </font>experiences <font color="blue">manufacturing</font> or     <font color="blue">distribution</font>  <font color="blue">difficult</font>ies,  does  not <font color="blue">actively market</font> Xolair or other     partnered  anti-IgE  products  or does not otherwise perform under our     <font color="blue">collaboration</font> <font color="blue">agreements</font>, our potential for <font color="blue">revenue from</font> these <font color="blue">products will</font>     be  <font color="blue">dramatically</font>  reduced</td>
    </tr>
    <tr>
      <td><font color="blue">Novartis  </font>and  <font color="blue">Genentech </font><font color="blue">may terminate</font> our     <font color="blue">collaboration</font> <font color="blue">agreements</font>, and, in that event, we would experience increased     capital <font color="blue"><font color="blue">requirement</font>s</font> to undertake <font color="blue">development</font> and <font color="blue">marketing at</font> our expense</td>
    </tr>
    <tr>
      <td>We  <font color="blue">cannot assure</font> you that we would be able to <font color="blue">manufacture</font>, market and     distribute Xolair on our own</td>
    </tr>
    <tr>
      <td>We may need <font color="blue">additional</font> financing, but our access to <font color="blue">capital funding</font> is     uncertain, and issuance of <font color="blue">additional</font> <font color="blue">common stock</font> could dilute existing     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Our  current  and anticipated <font color="blue">development</font> projects require substantial     <font color="blue">additional</font> capital</td>
    </tr>
    <tr>
      <td>While we expect that our cash on hand, together with our     <font color="blue">revenue from</font> Xolair, will fund our existing <font color="blue">operations</font> for the next four     years, our <font color="blue">future cash</font> needs <font color="blue">will depend on</font> many factors, including the     <font color="blue">commercial success</font> of Xolair, receiving royalty, profit-sharing, milestone     and <font color="blue">manufacturing</font>-rights payments from our <font color="blue"><font color="blue">collaboration</font> partners</font>, making     progress in our clinical <font color="blue">development</font> of TNX-355 and TNX-832 and in our     <font color="blue">preclinical efforts</font>, other research and <font color="blue"><font color="blue">development</font> activities</font>, and entering     into <font color="blue">additional</font> <font color="blue">collaboration</font> <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>Our capital <font color="blue"><font color="blue">requirement</font>s</font> may also     depend  on the progress and level of costs associated with preclinical     studies and <font color="blue"><font color="blue">clinical trial</font>s</font>, the costs associated with <font color="blue">acquisition</font>s of new     product  <font color="blue">candidates</font> by licensing or otherwise, the costs of preparing,     filing, prosecuting, maintaining and <font color="blue">enforcing patent</font> claims and other     <font color="blue">intellectual</font>  property  rights,  competing  <font color="blue">technological</font>  and  market     <font color="blue">development</font>s, changes in or <font color="blue">terminations</font> of existing <font color="blue">collaboration</font> and     licensing  <font color="blue">arrangements</font>  and  the  cost  of <font color="blue">manufacturing</font> scale-up and     <font color="blue">development</font> of <font color="blue">marketing activities</font>, if <font color="blue">undertaken by us</font></td>
    </tr>
    <tr>
      <td>We do not have     <font color="blue">committed external sources</font> of funding and we <font color="blue">cannot assure</font> you that we will     be  able to obtain <font color="blue">additional</font> funds on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>If     <font color="blue">adequate funds</font> are not available, we may be required to:           •   delay, reduce the scope of or <font color="blue">eliminate one</font> or more of our <font color="blue">development</font>     programs;           •   obtain funds through <font color="blue"><font color="blue">arrangements</font> with</font> <font color="blue"><font color="blue">collaboration</font> partners</font> or     others that may require us to <font color="blue">relinquish rights</font> to <font color="blue">technologies</font>, product     <font color="blue">candidates</font> or products that we <font color="blue">would otherwise seek</font> to develop or     <font color="blue">commercialize</font> ourselves; or           •   <font color="blue">license rights</font> to <font color="blue">technologies</font>, <font color="blue">product candidate</font>s or <font color="blue">products on</font>     terms that are less favorable to <font color="blue">us than might otherwise</font> be available</td>
    </tr>
    <tr>
      <td>28     ______________________________________________________________________    [59]Table of <font color="blue">Contents       </font>We may raise <font color="blue">additional</font> funds by issuing shares of our stock, which would     cause dilution to our <font color="blue">stockholders</font> and may <font color="blue"><font color="blue">adversely</font> affect</font> the <font color="blue">market price</font>     of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>New <font color="blue">investors could</font> have rights superior to existing     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If funding is insufficient at any time in the future, we may     be  unable to develop or <font color="blue">commercialize</font> our products, take advantage of     business <font color="blue">opportunities</font> or respond to <font color="blue">competitive pressures</font>, and our business     and <font color="blue">financial condition</font> may be harmed</td>
    </tr>
    <tr>
      <td>Risks Relating to Intellectual Property        The patentability, validity, enforceability and <font color="blue">commercial value</font> of our     patents are <font color="blue">highly uncertain</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">intellectual</font> property positions are     challenged, invalidated or <font color="blue">circumvented</font> and we fail to prevail in resulting     <font color="blue">intellectual</font> property <font color="blue">litigation</font>, our business could be <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in part on obtaining, maintaining and <font color="blue">enforcing patent</font>s     and  maintaining  trade  secrets</td>
    </tr>
    <tr>
      <td>While  we file and <font color="blue">prosecute patent</font>     <font color="blue">applications</font> to protect our inventions, our pending patent <font color="blue">applications</font> may     not result in the issuance of <font color="blue">valid patents</font> and our <font color="blue">issued <font color="blue">patents may</font></font> not     <font color="blue">provide competitive advantages</font></td>
    </tr>
    <tr>
      <td>Also, our <font color="blue">patents may</font> not <font color="blue">prevent others</font>     from developing <font color="blue">competitive products using</font> related or the same <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We  <font color="blue">cannot assure</font> you that pending patent <font color="blue">applications</font> developed by or     licensed to us will result in patents being issued or that, if issued, the     <font color="blue"><font color="blue">patents will</font> give us</font> an advantage over <font color="blue">competitors</font> with similar <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We own or have licenses to <font color="blue">certain issued patents</font></td>
    </tr>
    <tr>
      <td>The patents we own that     are most material to our business are five US patents and six foreign     patents relating to anti-IgE <font color="blue">antibodies</font></td>
    </tr>
    <tr>
      <td>However, the patent position of     <font color="blue">bio<font color="blue">technology</font></font> and <font color="blue">pharmaceutical</font> firms is <font color="blue">highly uncertain</font> and involves many     complex legal and technical issues</td>
    </tr>
    <tr>
      <td>There is <font color="blue">no clear policy involving</font> the     breadth of claims allowed or the degree of <font color="blue">protection afforded under such</font>     patents</td>
    </tr>
    <tr>
      <td>Issued patents can be challenged in <font color="blue">litigation</font> in the courts and in     <font color="blue">proceedings</font> in the <font color="blue">United States Patent and Trademark Office </font>and in courts     and  patent  offices in <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>Issuance of a patent is not     <font color="blue">conclusive as</font> to its validity, enforceability or the scope of its claim</td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot assure</font> you that our <font color="blue">patents will</font> not be <font color="blue">successfully</font> challenged as to     enforceability, invalidated or limited in the scope of their coverage</td>
    </tr>
    <tr>
      <td>Moreover,  <font color="blue">litigation</font> to uphold the validity of patents and to prevent     infringement can be very costly and can result in <font color="blue">diverting technical</font> and     management personnel’s time and attention, which may <font color="blue">materially</font> harm our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If the outcome of     <font color="blue">litigation</font> is adverse to us, <font color="blue">third parties</font> may be able to use our patented     <font color="blue">technology</font>  without paying us</td>
    </tr>
    <tr>
      <td>Moreover, we <font color="blue">cannot assure</font> you that our     patents  will  not be infringed or <font color="blue">successfully</font> avoided through design     innovation</td>
    </tr>
    <tr>
      <td>Any of these events may <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> our     business</td>
    </tr>
    <tr>
      <td>In addition to the <font color="blue">intellectual</font> property rights described above, we also     rely on unpatented <font color="blue">technology</font>, <font color="blue">trade secrets</font> and <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>We  cannot  assure  you  that  others  will  not <font color="blue">independently</font> develop     <font color="blue">substantially</font> equivalent information and <font color="blue">techniques</font> or <font color="blue">otherwise gain access</font>     to our <font color="blue">technology</font> or disclose such <font color="blue">technology</font>, or that we can <font color="blue"><font color="blue">effective</font>ly</font>     protect our rights in unpatented <font color="blue">technology</font>, <font color="blue">trade secrets</font> and <font color="blue">confidential</font>     information</td>
    </tr>
    <tr>
      <td>We require each of our employees, consultants and advisors to     execute a <font color="blue">confidential</font>ity agreement at the <font color="blue">commencement</font> of an <font color="blue">employment</font> or     consulting <font color="blue">relationship</font> with us</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you, however, that these     <font color="blue">agreements</font> will provide <font color="blue">effective</font> protection if an <font color="blue">unauthorized use</font> or     <font color="blue">disclosure</font> of this <font color="blue">confidential</font> information occurs</td>
    </tr>
    <tr>
      <td>If we fail to obtain any required patent license from <font color="blue">third parties</font>, our     product <font color="blue">development</font> efforts could be limited</td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial success</font> depends on our ability to operate <font color="blue">without infringing</font>     the patents and other <font color="blue"><font color="blue">proprietary</font> rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Other companies,     some of which may be our <font color="blue">competitors</font>, have filed <font color="blue">applications</font> for or have     <font color="blue">been issued patents</font>, and may obtain <font color="blue">additional</font> patents and <font color="blue">proprietary</font>     rights,  relating  to  products or <font color="blue">processes used</font> in, <font color="blue">necessary</font> to, or     otherwise related to our products and <font color="blue">product candidate</font>s</td>
    </tr>
    <tr>
      <td>29     ______________________________________________________________________    [60]Table of <font color="blue">Contents       </font>For example, we are aware of <font color="blue">broad patents</font> owned by others relating to the     <font color="blue">manufacture</font>, use and sale of <font color="blue"><font color="blue">recombinant</font> humanized <font color="blue">antibodies</font></font></td>
    </tr>
    <tr>
      <td>Many of our     product  <font color="blue">candidates</font>  are  <font color="blue">genetically</font> engineered <font color="blue">recombinant</font> humanized     <font color="blue">antibodies</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">antibody product</font>s or their <font color="blue">commercial use</font> or production     meet all of the <font color="blue"><font color="blue">requirement</font>s</font> of any of the claims of the <font color="blue">aforementioned</font>     patents, or other <font color="blue">third party patents</font> or patent <font color="blue">applications</font>, then we may     need a license to one or more of these patents</td>
    </tr>
    <tr>
      <td>We expect to seek to obtain     <font color="blue">patent licenses</font> when, in our judgment, such licenses are needed</td>
    </tr>
    <tr>
      <td>Even if we     determine that a license is not <font color="blue">necessary</font>, a <font color="blue">patent holder could disagree</font>     and sue us for damages and seek to <font color="blue">prevent us from</font> <font color="blue">manufacturing</font>, selling or     developing our products</td>
    </tr>
    <tr>
      <td>If any patent holder <font color="blue">successfully</font> <font color="blue">challenges</font> our judgment that our     products do not infringe their patents or that their patents are invalid, we     could be required to pay costly damages or to obtain a license to sell or     develop our drugs</td>
    </tr>
    <tr>
      <td>If we determine that a license is required, there can be     no assurance that we will be able to obtain the license on <font color="blue">commercially</font>     <font color="blue">reasonable terms</font>, if at all</td>
    </tr>
    <tr>
      <td>If we are unable to secure a required license,     we  might  be <font color="blue">prevented from using certain</font> of our <font color="blue">technologies</font> for the     <font color="blue">generation</font> and <font color="blue">manufacture</font> of our <font color="blue">recombinant</font> <font color="blue">antibody product</font>s or from     pursuing  product <font color="blue">development</font>, <font color="blue">manufacturing</font> or <font color="blue">commercialization</font> in a     <font color="blue">particular field</font>, and this may <font color="blue">materially</font> harm our business and financial     prospects</td>
    </tr>
    <tr>
      <td>In addition to patents, we <font color="blue">rely on <font color="blue">trade secrets</font></font> and <font color="blue">proprietary</font> know-how</td>
    </tr>
    <tr>
      <td>We <font color="blue">seek protection</font> in part through <font color="blue">confidential</font>ity <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>We cannot     assure  you,  however,  that  these <font color="blue">agreements</font> will provide meaningful     protection of our <font color="blue">proprietary</font> information or <font color="blue">trade secrets</font> in the event of     an <font color="blue">unauthorized use</font> or <font color="blue">disclosure</font> or that our valuable <font color="blue">trade secrets</font> will     not <font color="blue">become known</font> to, or <font color="blue">independently</font> developed, by our <font color="blue">competitors</font></td>
    </tr>
  </tbody>
</table>